¥3,267.00
3.00%
Tokyo, Nov 16, 11:30 am JST. Market open.
ISIN
JP3347200002
Symbol
4507
Index

Shionogi & Stock price

¥3,172.00
+357.50 12.70% 1M
+194.00 6.51% 6M
+331.00 11.65% YTD
+440.00 16.11% 1Y
+811.33 34.37% 3Y
+679.67 27.27% 5Y
+1,439.33 83.07% 10Y
+2,485.33 361.94% 20Y
Tokyo, Closing price Fri, Nov 13 2026
+34.00 1.08%
ISIN
JP3347200002
Symbol
4507
Index
Industry

AI Insights on Shionogi & Insights AI Insights on Shionogi &

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Is Shionogi & a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
¥2.8t
Enterprise Value
¥2.7t
Net debt
positive
Cash
¥707.8b
Shares outstanding
851.2m
Valuation
P/E
11.2
P/S | estimate
4.3 | 3.9
EV/Sales | estimate
4.3 | 3.8
EV/FCF | ex SBC
12.2 | -
P/B
1.6
Dividends
DPS
¥86.00
Yield 1Y | 5Y
2.7% | 2.6%
Growth 1Y | 5Y
21.1% | 17.5%
Payout 1Y | 3Y
29.5% | 29.6%
Increased
15 Years
Financials
Revenue | estimate
¥637.1b | ¥712.9b
EBITDA
¥242.5b
EBIT
¥207.2b
Net Income
¥241.2b
Free Cash Flow | ex SBC
¥223.4b | -
Growth
Revenue | estimate
45.7% | 42.7%
EBITDA
53.0%
EBIT
33.2%
Net Income
41.2%
Free Cash Flow
23.3%
Margin
Gross
81.6%
EBITDA
38.1%
EBIT
32.5%
Net
37.9%
Free Cash Flow | ex SBC
35.1% | -
Financial Health
Equity Ratio
65.4%
Return on Equity
12.2%
ROCE
11.4%
ROIC
11.4%
Debt/Equity
0.4
More
EPS
¥283.3
FCF per Share
¥262.5
Short interest
-
Employees
5k
Rev per Employee
¥100.8m

Shionogi & Stock Analysis

Unlock Scores for Free

Analyst Opinions

17 Analysts have issued a Shionogi & forecast:

9x Buy
53%
8x Hold
47%

Analyst Opinions

17 Analysts have issued a Shionogi & forecast:

Buy
53%
Hold
47%

Financial data from Shionogi &

Sep '26
+/-
%
637,089 637,089
46% 46%
100%
- Direct Costs 116,990 116,990
86% 86%
18%
520,099 520,099
39% 39%
82%
- Selling and Administrative Expenses 163,988 163,988
53% 53%
26%
- Research and Development Expense 137,836 137,836
32% 32%
22%
242,515 242,515
53% 53%
38%
- Depreciation and Amortization 35,317 35,317
1,084% 1,084%
6%
EBIT (Operating Income) EBIT 207,198 207,198
33% 33%
33%
Net Profit 241,163 241,163
41% 41%
38%

In millions JPY.

Don't miss a Thing! We will send you all news about Shionogi & directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Shionogi & Stock News

Neutral
Business Wire
●
26 days ago
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections. Cefiderocol data highlights at IDWeek will include new U.S. real-world ...
Neutral
Business Wire
●
about one month ago
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that its Board of Directors, at a meeting held on October 5, 2026, approved Shionogi entering into an agreement to acquire IntraBio Inc. (Head Office: Austin, TX; hereinafter “IntraBio”), a biopharmaceutical company developing and commer...
Positive
WSJ
●
about one month ago
The Japanese drugmaker said IntraBio's expertise would strengthen capabilities across its rare disease pipeline.
More Shionogi & News

Company Profile

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Head office Japan
CEO Mr. Teshirogi
Employees 4,955
Founded 1878
Website www.shionogi.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today